I'm LongbridgeAI, I can summarize articles.Q32 Bio reported a narrowed Q2 FY26 net loss of $8.95 million, with EPS improving to $0.44. R&D expenses decreased by 17.48% due to lower ADX-097 spending following its sale, while G&A costs rose 21.17%. Cash reserves increased to $106.27 million, supported by a recent public offering raising approximately $200 million. Additionally, the Bempikibart Phase 2a SIGNAL-AA Part B trial showed a 35.3% mean SALT reduction at Week 36.
- Q32 Bio posted a net loss of USD 8.95 million, narrowing from USD 9.49 million a year earlier; loss per share improved to USD 0.44. * R&D expense fell 17.48% to USD 4.26 million, due to lower ADX-097 spend after the program’s November 2025 sale. * G&A costs rose 21.17% to USD 4.86 million on higher stock-based compensation and other expenses. * Cash and cash equivalents climbed to USD 106.27 million; July public offering raised about USD 200 million gross. * Bempikibart Phase 2a SIGNAL-AA Part B showed 35.3% mean SALT reduction at Week 36; 40% achieved SALT-20 in mITT. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608050659PR_NEWS_USPR_____NE19049) on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)